Table 1 Patients and tumour characteristics
Variable | Number of patients (%) |
|---|---|
Number of the patients Grade | 53 (aged 40–94, mean 67) |
I | 7 (13.2%) |
II | 24 (45.3%) |
III | 18 (34%) |
in situ II | 1 (1.9%) |
in situ III | 3 (5.7%) |
Axillary nodal status | |
N0 | 25 (47.2%) |
N1–3 | 12 (22.6%) |
N4–9 | 11 (20.8%) |
>N10 | 3 (5.7%) |
Unknown (axillary evacuation done 1993 and 1994) | 2 (3.8%) |
Tumour size | |
≤ 2 cm | 13 (24.5%) |
> 2 cm | 40 (75.5%) |
Estrogen receptor status (ER) 1) | |
Positive | 35 (66%) |
Negative | 14 (26.4%) |
Positive in DCI | 3 (5.7%) |
Negative in DCIS | 1 (1.9%) |
Progesterone receptor status (PR) 1) | |
Positive | 36 (68%) |
Negative | 13 (24.5%) |
Positive in DCIS | 3 (5.7%) |
Negative in DCIS | 1 (1.9%) |
Ki-67 status | |
<5% | 7 (13.2%) |
5–19% | 16 (30.2%) |
20–29% | 8 (15.1%) |
>20% | 22 (41.5%) |
Histologic type | |
Ductal | 37 (69.8%) |
Lobular | 8 (15.1%) |
Subtypes | 4 (7.5%) |
Ductal carcinoma in situ | 4 (7.5%) |
Her-2 2) | |
IHC positive (2+ and 3+) | 20 (37.7%) |
IHC negative (0 and 1+) | 29 (54.7%) |
IHC positive in DCIS | 2 (3.8%) |
IHC negative in DCIS | 2 (3.8%) |
CISH positive | 10 (18.9%) |
CISH positive in DCIS | 2 (3.8%) |
CK 5/6 3) | |
Triple-negative (ER-, PR-, Her-2/neu-) | 11 (20.8%) |
Basal-like carcinoma (ER-, PR-, Her-2/neu-, CK5/6+) | 8 (15.1%) |